Policy
The 2022 midterm elections caused November to be a monumental month for drug policy developments in the United States. While not every attempted effort was passed, many were successful. Kicking things off, Colorado voters approved a statewide measure to decriminalize natural psychedelics and create a model to legally purchase them. These changes will roll out gradually over the course of the next four years.
With nearly 70% of Americans in favor of legalizing cannabis, it’s no surprise that there were several victories in reforming cannabis policies across the country. Maryland and Missouri both legalized marijuana, becoming the 20th and 21st states to do so. Meanwhile, voters in Ohio, Wisconsin, and Texas approved a variety of cannabis-related drug policy reforms.
In addition to the midterm elections, bipartisan lawmakers in Congress formed a new first-of-its-kind “psychedelic caucus” which will “focus on exploring psychedelic research to alleviate the U.S. mental health crisis.” The congressional Psychedelics Advancing Clinical Treatments (PACT) caucus will not be advocating for drug policy reforms but will instead focus congressional conversations around the therapeutic potential of psychedelics and work toward educating lawmakers and the public.
Across the pond, the Netherlands is planning to ban nitrous oxide due to concerns that the drug will cause severe health issues in addition to the thousands of vehicular crashes the country has been experiencing between 2018 and 2021. The Dutch government is expected to confirm the ban on distribution, sale, and possession of nitrous oxide in January.
Industry
A psychedelic entrepreneur in Florida opened an above-board shroom dispensary. Well, sort of… rather than selling psilocybin mushroom products, the hemp dispensary is selling Amanita muscaria, the red-and-white dotted mushroom species that engenders psychoactive effects when consumed. This is yet another example of newly-formed businesses operating in legal gray areas involving psychoactive drugs, and it will be interesting to see if the shop is able to stay open now that word has spread about its trippy offerings.
Research
The final participant in the Multidisciplinary Association for Psychedelic Studies (MAPS) Phase 3 trial of MDMA-assisted therapy for PTSD completed their last session in the clinical treatment protocol, bringing the study to a close. The next step in the process will be an FDA evaluation of the treatment’s safety and efficacy, which will take place next year. It’s been a long ride for MAPS, which started the work of obtaining FDA approval to use MDMA therapeutically 36 years ago!
Compass Pathways published results from its Phase 2 clinical trial of psilocybin-assisted therapy for depression, and they left a little to be desired. Although the treatment yielded rapid antidepressant effects for most patients, only about 20% of participants still showed significant improvement at 12 weeks. These results are roughly as effective as existing SSRIs or traditional therapeutic treatments for depression like cognitive behavioral therapy.
A couple studies looking into ayahuasca found that the South American brew causes adverse side effects, but the benefits still outweigh the risks. This seems to me to be common sense, because the use of practically all psychedelics involves some negative side effects but as they say, “the juice is still worth the squeeze” in my opinion.
Harm Reduction
A survey analyzed responses from about 250,000 festival attendees and found that drug checking services create a safer environment. The study focused on both positive and negative impacts of on-site drug checking and concluded that not only did the service not result in an increase of drugs at festivals, but about 61% of people who used them disposed of drugs they were intending to take if they were unsure what they contained. In addition, the seven festivals that provided drug checking services did not incur a single drug-related death.
Miscellaneous
The U.S. National Park Service (NPS) issued a warning asking people to not lick toads that secrete 5-MeO-DMT, a psychedelic alkaloid present in the Sonoran desert toad. This messaging appears to have been shared even though there hasn’t been a noted increase in toad-licking happening in national parks. Besides, every psychonaut worth their salt knows that you don’t lick the toad, you smoke the extracted secretion! Nonetheless, it’s entertaining to see the U.S. government attempt to communicate with the public about psychedelic drugs, even if they aren’t getting all of the details right.
Wrapping up this month’s recap is a study of ancient human remains that found that a Nazca child consumed San Pedro cactus prior to being sacrificed in a ritual ceremony more than a thousand years ago. This is not the first study to find a history of psychedelic use prior to ritual sacrifice, indicating that this may have been a more widespread practice than it was once thought to be.
That’s all for this month’s update. Remember to always test and weigh your drugs and until next time—keep thinking wilder.
Think Wilder is reader-supported. If you enjoyed this month’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.
